---
title: "Enhertu potential broadens as new data point to frontline breast cancer role"
date: Mon, 02 Jun 2025 08:00:00 -0400
source: "BioPharmaDive"
link: "https://www.biopharmadive.com/news/astrazeneca-daiichi-enhertu-first-line-breast-cancer-her2-asco/749497/"
---

<figure><div><img src="https://imgproxy.divecdn.com/tfZMC0WLVN47-TOzwHzBKMdkUNzZ_Y-o7BPFQP8QRCc/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjA0Nzk1NTY1LmpwZw==.webp" /></div></figure><p>Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that's been standard treatment for more than a decade.</p>